Jazz Pharmaceuticals (NASDAQ: JAZZ) and Soligenix (NASDAQ:SNGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Insider & Institutional Ownership

89.3% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.2% of Soligenix shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares Jazz Pharmaceuticals and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals 30.14% 22.63% 10.74%
Soligenix -90.93% -112.81% -71.98%

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Soligenix’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jazz Pharmaceuticals $1.62 billion 5.23 $396.83 million $7.95 17.79
Soligenix $10.45 million 1.70 -$3.24 million ($1.04) -1.95

Jazz Pharmaceuticals has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Jazz Pharmaceuticals and Soligenix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals 0 5 14 0 2.74
Soligenix 0 1 1 0 2.50

Jazz Pharmaceuticals currently has a consensus price target of $181.95, suggesting a potential upside of 28.63%. Soligenix has a consensus price target of $3.85, suggesting a potential upside of 89.66%. Given Soligenix’s higher probable upside, analysts plainly believe Soligenix is more favorable than Jazz Pharmaceuticals.


Jazz Pharmaceuticals beats Soligenix on 12 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.